Hospital acquired infections (HAI) or diseases, also called as nosocomial infections are acquired in healthcare in-patient settings. It is estimated that in the U.S., 9.2 out of every 100 parents acquire hospital infection. Urinary tract infection and pneumonia are the most common types of HAI, followed by bloodstream infection, and surgical site infection. These infections are caused by pathogens, among patients with compromised immunity. Patients may also develop HAIs due to sub-standard healthcare settings and negligence on the part of hospital staff. The mortality and morbidity of HAIs and the associated costs has urged caregivers for devising efficient infection control strategies. Accurate and in-time diagnosis of HAIs are vital for efficient control and management of HAI.

The global hospital acquired disease testing market report studies this market in terms of major types of HAIs. These include hospital-acquired pneumonia, urinary tract infection, bloodstream infection, surgical site infection, Methicillin-resistant Staphylococcus aureus (MRSA) and others. 

Qualitative information such as drivers, challenges, and future prospects for the global hospital acquired disease testing market are included in this report. Competition assessment tools such as fractal map analysis and attractive investment proposition are presented in this study for scrutinizing competition of the global hospital acquired disease testing market. This study concludes with company profiles section that highlights information about the key companies engaged in development, manufacture and provision of hospital acquired disease testing products.

Infection Type Segmentation Investigation

Pneumonia and urinary tract infection are the most common hospital acquired infections and the largest market segments in 2015. Nosocomial pneumonia, healthcare associated pneumonia and ventilator-associated pneumonia are the chief causes of mortality and morbidity in hospital settings. Surgical site infection is the third common nosocomial infection and involves skin, muscle and subcutaneous tissue. The attributable mortality of blood stream infection is 20%, thus making this segment among the deadliest conditions and thus the most addressable.

North America is the largest market for hospital-acquired disease testing, due to multitude of hospital admissions, and the growing need for containment of rising morbidity. Stringent guidelines for infection reduction and thus culminating the risk of readmission in hospitals have urged the emerging markets to grow at a rapid CAGR during the forecast period.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Hospital Acquired Disease Testing market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Hospital Acquired Disease Testing market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Hospital Acquired Disease Testing market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Hospital Acquired Disease Testing market?
• Which is the largest regional market for Hospital Acquired Disease Testing market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Hospital Acquired Disease Testing market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Hospital Acquired Disease Testing market worldwide?